High circulating levels of midregional proenkephalin A predict vascular dementia: a population-based prospective study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 05 2020
15 05 2020
Historique:
received:
26
07
2018
accepted:
09
04
2020
entrez:
17
5
2020
pubmed:
18
5
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Midregional Pro-enkephalin A (MR-PENK A) and N-terminal Protachykinin A (NT-PTA) have been associated with vascular dementia. However, the longitudinal relationship between these biomarkers and incident dementia has not been fully investigated. In the population-based Malmö Preventive Project, circulating levels of MR-PENK A and NT-PTA were determined in a random sample of 5,323 study participants (mean age: 69 ± 6 years) who were followed-up over a period of 4.6 ± 1.6 years. The study sample included 369 patients (7%) who were diagnosed in the same period with dementia. We analyzed relationship of MR-PENK A and NT-PTA with the risk of developing dementia by using multivariable-adjusted Cox regression models adjusted for traditional risk factors. Increased plasma levels of MR-PENK A were associated with higher risk of incident vascular dementia whereas no associations were found with all-cause or Alzheimer dementia. The risk of vascular dementia was mainly conferred by the highest quartile of MR-PENK as compared with lower quartiles. Elevated levels of NT-PTA yielded significant association with all-cause dementia or dementia subtypes. Elevated plasma concentration of MR-PENK A independently predicts vascular dementia in the general population. MR-PENK A may be used as an additional tool for identifying vascular subtype in ambiguous dementia cases.
Identifiants
pubmed: 32415209
doi: 10.1038/s41598-020-64998-y
pii: 10.1038/s41598-020-64998-y
pmc: PMC7229155
doi:
Substances chimiques
Biomarkers
0
Enkephalins
0
Protein Precursors
0
proenkephalin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8027Références
Sorbi, S. et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur. J. Neurol. 19, 1159–1179, https://doi.org/10.1111/j.1468-1331.2012.03784.x (2012).
doi: 10.1111/j.1468-1331.2012.03784.x
pubmed: 22891773
Prince, M. World Alzheimer Report 2016 (2016).
Rizzi, L., Rosset, I. & Roriz-Cruz, M. Global epidemiology of dementia: Alzheimer’s and vascular types. BioMed. Res. Int. 2014, 908915, https://doi.org/10.1155/2014/908915 (2014).
doi: 10.1155/2014/908915
pubmed: 25089278
pmcid: 4095986
Kalaria, R. N., Akinyemi, R. & Ihara, M. Does vascular pathology contribute to Alzheimer changes? J. neurological Sci. 322, 141–147, https://doi.org/10.1016/j.jns.2012.07.032 (2012).
doi: 10.1016/j.jns.2012.07.032
Fillit, H., Nash, D. T., Rundek, T. & Zuckerman, A. Cardiovascular risk factors and dementia. Am. J. Geriatr. Pharmacother. 6, 100–118, https://doi.org/10.1016/j.amjopharm.2008.06.004 (2008).
doi: 10.1016/j.amjopharm.2008.06.004
pubmed: 18675769
Miralbell, J. et al. Cognitive patterns in relation to biomarkers of cerebrovascular disease and vascular risk factors. Cerebrovasc. Dis. 36, 98–105, https://doi.org/10.1159/000352059 (2013).
doi: 10.1159/000352059
pubmed: 24029412
Ernst, A., Kohrle, J., Bergmann, A. & Proenkephalin, A. 119–159, a stable proenkephalin A precursor fragment identified in human circulation. Peptides 27, 1835–1840, https://doi.org/10.1016/j.peptides.2006.03.008 (2006).
doi: 10.1016/j.peptides.2006.03.008
pubmed: 16621157
Ernst, A., Suhr, J., Kohrle, J. & Bergmann, A. Detection of stable N-terminal protachykinin A immunoreactivity in human plasma and cerebrospinal fluid. Peptides 29, 1201–1206, https://doi.org/10.1016/j.peptides.2008.02.006 (2008).
doi: 10.1016/j.peptides.2008.02.006
pubmed: 18374454
Ernst, A. et al. Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. J. Neuroimmunol. 221, 62–67, https://doi.org/10.1016/j.jneuroim.2010.02.004 (2010).
doi: 10.1016/j.jneuroim.2010.02.004
pubmed: 20207019
Doehner, W. et al. Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J. Am. Coll. Cardiology 60, 346–354, https://doi.org/10.1016/j.jacc.2012.04.024 (2012).
doi: 10.1016/j.jacc.2012.04.024
Fedorowski, A. et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur. heart J. 31, 85–91, https://doi.org/10.1093/eurheartj/ehp329 (2010).
doi: 10.1093/eurheartj/ehp329
pubmed: 19696189
Fava, C. et al. Prediction of blood pressure changes over time and incidence of hypertension by a genetic risk score in Swedes. Hypertension 61, 319–326, https://doi.org/10.1161/HYPERTENSIONAHA.112.202655 (2013).
doi: 10.1161/HYPERTENSIONAHA.112.202655
pubmed: 23232644
Holm, H. et al. N-Terminal Prosomatostatin and Risk of Vascular Dementia. Cerebrovasc. Dis. 44, 259–265, https://doi.org/10.1159/000479940 (2017).
doi: 10.1159/000479940
pubmed: 28854435
Melander, O. et al. Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk. J. Clin. oncology: Off. J. Am. Soc. Clin. Oncol. 33, 2632–2638, https://doi.org/10.1200/JCO.2014.59.7682 (2015).
doi: 10.1200/JCO.2014.59.7682
Denning, G. M. et al. Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissues. Peptides 29, 83–92, https://doi.org/10.1016/j.peptides.2007.11.004 (2008).
doi: 10.1016/j.peptides.2007.11.004
pubmed: 18082911
Comb, M., Seeburg, P. H., Adelman, J., Eiden, L. & Herbert, E. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature 295, 663–666 (1982).
doi: 10.1038/295663a0
Arbit, B. et al. Prognostic Usefulness of Proenkephalin in Stable Ambulatory Patients With Heart Failure. Am. J. cardiology 117, 1310–1314, https://doi.org/10.1016/j.amjcard.2016.01.042 (2016).
doi: 10.1016/j.amjcard.2016.01.042
Rinne, J. O. et al. Brain methionine- and leucine-enkephalin receptors in patients with dementia. Neurosci. Lett. 161, 77–80 (1993).
doi: 10.1016/0304-3940(93)90144-A
Shen, Y. & Li, R. The role of neuropeptides in learning and memory: possible mechanisms. Med. hypotheses 45, 529–538 (1995).
doi: 10.1016/0306-9877(95)90235-X
Reisberg, B. et al. Effects of naloxone in senile dementia: a double-blind trial. N. Engl. J. Med. 308, 721–722, https://doi.org/10.1056/NEJM198303243081213 (1983).
doi: 10.1056/NEJM198303243081213
pubmed: 6338389
Younes, A., Pepe, S., Yoshishige, D., Caffrey, J. L. & Lakatta, E. G. Ischemic preconditioning increases the bioavailability of cardiac enkephalins. Am. J. Physiol. Heart circulatory physiology 289, H1652–1661, https://doi.org/10.1152/ajpheart.01110.2004 (2005).
doi: 10.1152/ajpheart.01110.2004
Iliodromitis, E. K., Lazou, A. & Kremastinos, D. T. Ischemic preconditioning: protection against myocardial necrosis and apoptosis. Vasc. health risk Manag. 3, 629–637 (2007).
pubmed: 18078014
pmcid: 2291307
Iadecola, C. The pathobiology of vascular dementia. Neuron 80, 844–866, https://doi.org/10.1016/j.neuron.2013.10.008 (2013).
doi: 10.1016/j.neuron.2013.10.008
pubmed: 24267647
van den Brink, O. W. et al. Endogenous cardiac opioids: enkephalins in adaptation and protection of the heart. Heart, lung circulation 12, 178–187, https://doi.org/10.1046/j.1444-2892.2003.00240.x (2003).
doi: 10.1046/j.1444-2892.2003.00240.x
pubmed: 16352129
Pandav, R., Dodge, H. H., DeKosky, S. T. & Ganguli, M. Blood pressure and cognitive impairment in India and the United States: a cross-national epidemiological study. Arch. Neurol. 60, 1123–1128, https://doi.org/10.1001/archneur.60.8.1123 (2003).
doi: 10.1001/archneur.60.8.1123
pubmed: 12925370
Launer, L. J. et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 21, 49–55 (2000).
doi: 10.1016/S0197-4580(00)00096-8
Austin, B. P. et al. Effects of hypoperfusion in Alzheimer’s disease. J. Alzheimer’s disease: JAD. 26(Suppl 3), 123–133, https://doi.org/10.3233/JAD-2011-0010 (2011).
doi: 10.3233/JAD-2011-0010
Roman, G. C. Brain hypoperfusion: a critical factor in vascular dementia. Neurological Res. 26, 454–458, https://doi.org/10.1179/016164104225017686 (2004).
doi: 10.1179/016164104225017686
Ueno, M. et al. Blood-brain barrier damage in vascular dementia. Neuropathology 36, 115–124, https://doi.org/10.1111/neup.12262 (2016).
doi: 10.1111/neup.12262
pubmed: 26607405
Erdo, F., Denes, L. & de Lange, E. Age-associated physiological and pathological changes at the blood-brain barrier: A review. J. Cereb. Blood Flow. Metab. 37, 4–24, https://doi.org/10.1177/0271678X16679420 (2017).
doi: 10.1177/0271678X16679420
pubmed: 27837191
Sagare, A. P., Sweeney, M. D., Makshanoff, J. & Zlokovic, B. V. Shedding of soluble platelet-derived growth factor receptor-beta from human brain pericytes. Neurosci. Lett. 607, 97–101, https://doi.org/10.1016/j.neulet.2015.09.025 (2015).
doi: 10.1016/j.neulet.2015.09.025
pubmed: 26407747
pmcid: 4631673
Zlokovic, B. V., Lipovac, M. N., Begley, D. J., Davson, H. & Rakic, L. Transport of leucine-enkephalin across the blood-brain barrier in the perfused guinea pig brain. J. Neurochem. 49, 310–315 (1987).
doi: 10.1111/j.1471-4159.1987.tb03431.x
Balog, T., Sobocanec, S., Sverko, V. & Marotti, T. Met-enkephalin modulates resistance to oxidative stress in mouse brain. Neuropeptides 38, 298–303, https://doi.org/10.1016/j.npep.2004.05.010 (2004).
doi: 10.1016/j.npep.2004.05.010
pubmed: 15464195
Bennett, S., Grant, M. M. & Aldred, S. Oxidative stress in vascular dementia and Alzheimer’s disease: a common pathology. J. Alzheimers Dis. 17, 245–257, https://doi.org/10.3233/JAD-2009-1041 (2009).
doi: 10.3233/JAD-2009-1041
pubmed: 19221412
Dahl, A., Berg, S. & Nilsson, S. E. Identification of dementia in epidemiological research: a study on the usefulness of various data sources. Aging Clin. Exp. Res. 19, 381–389, https://doi.org/10.1007/bf03324718 (2007).
doi: 10.1007/bf03324718
pubmed: 18007116
Jin, Y. P., Gatz, M., Johansson, B. & Pedersen, N. L. Sensitivity and specificity of dementia coding in two Swedish disease registries. Neurology 63, 739–741, https://doi.org/10.1212/01.wnl.0000134604.48018.97 (2004).
doi: 10.1212/01.wnl.0000134604.48018.97
pubmed: 15326258